Senior executives from Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, will be available on stand number 40E04 to discuss the success the company has generated from its innovative, industry-first sterile pharmaceutical manufacturing back-up supply programme to manage the risk of supply interruption, which it launched earlier this year.
‘With regulatory scrutiny increasing, we recognise how important it is for pharmaceutical companies to have established sterile back-up supply agreements in place,’ said Geoffrey M. Glass, Patheon’s executive vice president of global sales and marketing. ‘Our programme has brought a prudent way to manage the risk of supply interruption without building the capacity internally or committing to onerous volume obligations with a contract manufacturing partner.
‘We have generated a lot of interest, as both new and existing customers have signed both back-up and primary manufacturing agreements since the programme was launched. They have recognised the benefit of getting an insurance policy on their sterile supply, which is largely offset by the tech transfer investment.’
Several companies have moved back-up or primary supply for sterile products since the launch of the programme. The Medicines Company, Photocure and others now utilise Patheon’s industry leading facilities in Italy to manufacture their sterile products.
Patheon representatives will be available to discuss the company’s back-up sterile supply programme on stand 40E04 at CPhI Worldwide in Frankfurt, Germany from 25 –27 October 2011.